Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA To view or add a comment, sign in FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials
But lets assume for a second that this plays out
doi: 10.1016/j.ejps.2025.107073 Summary Keywords hepatoprotection, hepatotoxicity, morin, nano-formulations, oxidative stress, synergistic therapy Citation Sivalingam AM (2026) Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity
Specifically, retatrutide simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor which reduces appetite and slows gastric emptying [6] [7] GIP (glucose-dependent insulinotropic polypeptide) receptor which enhances insulin secretion and may improve fat metabolism [9] [10] Glucagon receptor which may increase energy expenditure and, based on early clinical and preclinical data, could promote hepatic fat metabolism This triple-action mechanism sets retatrutide apart from existing approved therapies such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
In doing so, we can make our home a safer place, help safeguard our community and protect our environment
Senate voted 53-45 to confirm Dr
